A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer

Clin Cancer Res. 2021 Apr 6:clincanres.0324.2021. doi: 10.1158/1078-0432.CCR-21-0324. Online ahead of print.ABSTRACTTo evaluate feasibility and efficacy, checkpoint inhibitor atezolizumab was added to neoadjuvant chemoradiotherapy prior to surgery for esophagogastric adenocarcinoma. The approach was deemed feasible, and while it did not demonstrate better clinical outcome to propensity-matched patients, biomarker investigation demonstrated that high inflammation in the sample at baseline predicted therapeutic benefit.PMID:33824165 | DOI:10.1158/1078-0432.CCR-21-0324
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research